Physician profile
Vimalson V Monickam
NPI 1669556726
$2,170.44
in general payments reported to CMS, 2019-2025
16 companies · $96.47 in 2025
The $96.47 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $142 · 2022: $252 · 2024: $272 · 2025: $96.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $374.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $343.40 | 2019 | |
| Glaxosmithkline, LLC. | $246.95 | 2019-2022 | |
| Abbott Laboratories | $150.00 | 2024 | Freestyle Libre 3 |
| Medtronic, INC. | $127.23 | 2022 | |
| Neurocrine Biosciences, INC. | $125.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2019 | |
| Indivior INC. | $124.98 | 2020 | |
| Sunovion Pharmaceuticals INC. | $124.93 | 2019 | |
| Lilly USA, LLC | $122.19 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $121.43 | 2019 | |
| Boston Scientific Corporation | $96.47 | 2025 | Watchman Flx |
| Allergan, INC. | $35.54 | 2019-2020 | |
| Janssen Biotech, INC. | $22.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.12 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vimalson Monickam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.